Academic Research Library

Find some of the best Journals and Proceedings.

Neuroimaging of High-Grade Gliomas: Correla on Between 3T MRI Findings and Histopathological Markers

Author : Baiturlin Zhanibek

Abstract :Introduction: High-grade gliomas (HGG) require precise preoperative evaluation to guide treatment strategy. Multimodal 3T MRI offers detailed morphological and metabolic information. Correlation with histopathological markers, such as IDH mutation and Ki-67 index, enhances diagnostic accuracy. Objective: To evaluate the diagnostic potential of 3T MRI for preoperative characterization of HGG and to determine its correlation with histopathological markers (IDH, Ki-67). Materials and Methods: We analyzed 103 patients with immunohistochemically confirmed gliomas (56 males, 47 females; mean 47.6). All underwent 3T MRI (GE Signa Architect). Protocol included conventional sequences (T1, T2, T2-FLAIR, DWI/ADC) and advanced modalities: SWAN, ASL/DSC perfusion, MRS (TE 35/144), and contrast-enhanced T1+Gad. Glioma grading was based on morphological features, IDH mutation status, and Ki-67 immunoexpression (MIB-1). Results: SWAN: neoangiogenesis, microhemorrhages, calcifications in 84.4%. Perfusion (ASL/DSC): increased CBF, rCBF, rCBV in 79.6%, reflecting vascular proliferation. MRS: elevated Cho/Cr in 67.9%; Lip/Lac peaks in 17.4%. DWI/ADC: restricted diffusion in 87.3%. T1+Gad: ring-shaped/heterogeneous enhancement, typical of HGG. Correlation with histopathology confirmed agreement with vascular proliferation in 85.4% of cases. Conclusion: Multimodal 3T MRI provides robust preoperative characterization of high-grade gliomas and demonstrates strong correlation with histopathological markers. This approach is particularly valuable when biopsy is not feasible or histological results are inconclusive.

Keywords :Radiology, Perfusion, Glioma, Diagnosis, Immunohistochemistry, MRI.

Conference Name :International Conference on Radiology and Physics of Medical Imaging (ICRPMI-25)

Conference Place Klaipeda, Lithuania

Conference Date 22nd Oct 2025

Preview